VICTORIA, BC, April 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery technology ...
Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical Development (NBCD) to expand the scope of its Phase 3 trial using its flagship product to treat ...
NBCD (Nordic Bioscience Clinical Development) to make strategic investment on the same terms of Eupraxia's recently completed IPO VICTORIA, BC , April 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results